1 / 10

Controls for Blood Septicemia Nucleic Acid Tests

Controls for Blood Septicemia Nucleic Acid Tests. Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland June 15, 2006. Sepsis: Infection of Blood Stream. Bacterial infection (Bacteremia); Fungal Infection (Candidemia)

jbonin
Télécharger la présentation

Controls for Blood Septicemia Nucleic Acid Tests

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Controls for Blood Septicemia Nucleic Acid Tests Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland June 15, 2006

  2. Sepsis: Infection of Blood Stream • Bacterial infection (Bacteremia); Fungal Infection (Candidemia) • Second leading cause of death among patients in non-coronary intensive care units (ICU) • Tenth leading cause of death overall in US • Usually diagnosed by culture using specialized apparatus to detect and identify any viable microorganisms. • Limitations of Blood Culture • Relatively insensitive and time consuming: 24 to 48 hrs to results • >30% of septic patients are false negative by blood culture

  3. Nucleic AcidTests for Sepsis Roche SeptiFastTM Test • Highly specific – able to detect <100 organisms per ml blood • Detects microorganisms that cause >90% of all blood stream infections • Real Time PCR on Light Cycler Platform • 3 parallel reactions: gram positive, gram negative, and fungus • Melting curve analysis of end product ensures proper sequence • Rapid, automated results in less than 5 hours

  4. ACCURUN 500 Design Specifications • Manufactured from P. aeruginosa,S. aureus, and C. albicans • Inactivated to reduce viability >6 logs. • Diluted in negative human plasma • Targeted at low concentration (about 300 CFU/ml ) Intended Use • Estimate laboratory testing precision • Detect errors in laboratory testing procedures. • Controls for the entire workflow

  5. Linearity of C. albicans in SeptiFast Test

  6. C. albicans Quantification -Channel 640 Tm Calling – Channel 640 100 cfu/reaction 100 cfu/reaction IC NHP NHP

  7. P. aeruginosa Tm Calling – Channel 670 Quantification -Channel 670 100 cfu/reaction NHP

  8. Excellent Reproducibility: Multiple Lots, Test Sites S. aureus P. aeriginosa C. albicans Test Site ATest Site B Test Site ATest Site B Test Site ATest Site B cp 1 2 3 1 2 3 • 2 3 1 2 3 • Lot Number 1 2 3 1 2 3 Mean: 19.0 20.1 16.8 SD: 0.8 0.6 0.6 %CV: 5% 4% 2%

  9. Stability Studies Accelerated Stability 37o C Freeze-Thaw Stability

  10. ACCURUN 500 Summary Stable, low reactive independent quality control material • Made from natural bacteria in plasma diluent to mimic clinical sample • Controls for all test steps: extraction, amplification and detection Well suited for the quality control of Nucleic Acid assays for microorganisms in human blood. • Gram positive, Gram negative and fungal controls showed amplification peaks only in the respective channels for all lots • Negative controls showed Internal Control peaks only • Excellent Reproducibility between Control Lots, Test Runs, and Test Sites Use of ACCURUN 500 will allow laboratories to detect immediate testing errors and monitor the long term performance of such assays.

More Related